PORTOLA VALLEY, Calif., July 29, 2011 /PRNewswire/ -- Spectros Corporation announced today that 2011 year-to-date sales revenue rose 51% (year-over-year) over the similar period in 2010. This continues the third year in a row for double-digit revenue growth for Spectros since the current T-Stat Tissue Oximeter product line was launched in 2008.
"This growth sends a clear signal that the market is embracing the Spectros state-of-the-art broadband VLS tissue oximetry," notes CFO John Bagnatori.
Spectros T-Stat® and Continuum® Tissue Oximeters are the only broadband tissue oximeters on the market in the U.S. and Europe. T-Stat® and Continuum® compete in the marketplace with INVOS® oximeters marketed by Covidien. An expanded array of probes, including Continuum® broadband cerebral probes currently being readied for manufacturing, pending FDA approval and release anticipated over the next year.
Spectros markets and licenses advanced molecular sensing and imaging devices that shed light on ischemia and cancer. The company's champion product, the T-Stat VLS Tissue Oximeter, is the first medical device FDA-approved as sensitive to ischemia, an insufficient supply of oxygen to tissue. T-Stat is the only commercially-available tissue oximeter that utilizes state-of-the-art multispectral visible light spectroscopy (VLS) technology. The non-invasive T-Stat VLS system is used clinically to provide a continuous and real-time absolute value, utilizing 260 wavelengths, over the competing NIRS oximeter product lines that only use 2-4.
Spectros also develops molecular diagnostic tools for breast and prostate cancer, currently in phase I/II clinical trials supported by the National Cancer Institute. Spectros is a venture-supported private concern and markets its products in the U.S. and internationally.
(Note: Forward-looking statements are intended as a guide only, and do not constitute an offer for investment nor a guarantee of future events or returns. Certain Spectros applications described above have not been reviewed and approved by the FDA, and are therefore labeled for investigational use only. T-Stat and Continuum are trademarks of the Spectros Corporation. INVOS is a trademark of Somanetics and Covidien).
For further information, visit www.spectros.com.
Copyright©2010 PR Newswire.
All rights reserved